echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Poxel SA announces positive top-line results for new oral anti-sugar drug imeglimin key phase III TIMES 3 study

    Poxel SA announces positive top-line results for new oral anti-sugar drug imeglimin key phase III TIMES 3 study

    • Last Update: 2020-06-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Poxel SACompany(http://announced the positive top-line results of the 36-week open label extension of the new oral sugar-reducing drug imeglimin key PHASE III TIMES 3 studyAbout TIMES 3
    TIMES 3 is a study in the Imeglimin PHASE III Clinical Development Project TIMES, which is evaluating the efficacy and safety of imeglimin in the treatment of patients with type 2 diabetes in Japan to support the safety and efficacy of imeglimin in different patient groupsThe project included three key Phase III studies involving more than 1,100 patients, in which imeglimin was given a dose of 1000 mg and taken orally twice dailyThe TIMES 2 results are expected by the end of 2019, after which Roxel will submit itsnew drug(http://(NDA) application in Japan in 2020 with partner SumitomoPharmaceutical(http://TIMES 3 is a 16-week, double-blind, placebo-controlled, randomized study with a 36-week open label extension periodThe study enrolled 215 patients with type 2 diabetes who received insulin-treated blood sugar level control in Japan and assessed the efficacy and safety of imeglimin and insulin combination therapyThe main endpoint of the study was the relative baseline change in the treatment of glycated hemoglobin A1c (HbA1c) at week 16   The 16-week portion of the study reached its main endpoint and a good safety and tolerance profile was observed, with the top line results released on June 25, 2019   The results showed that imeglimin combined insulin therapy showed significant lysing effects: in the 16th week of treatment, the relative baseline of HbA1c in the imeglimin-insulin therapy group was significantly reduced (the average change in the relative baseline of HbA1c after placebo correction was -0.60%), with statistically significant differences (p 0.0001) During 16 weeks of treatment, imeglimin was similar to placebo in terms of overall safety and tolerance The incidence of hypoglycemia was similar in 2 groups, with most hypoglycemia events being mild and no severe hypoglycemia events   the adverse event profile of imeglimin was consistent with the placebo and was consistent with the phase III TIMES 1 single-drug study and other imeglimin clinical studies 'The about imeglimin imeglimin belongs to a new class of oral chemicals called Glimins, which is the first candidate product (http:// to enter clinical development in this category of drug (http:// , with a unique mechanism of action   imeglimin has been shown to reduce blood sugar by increasing insulin secretion, increasing insulin sensitivity, and inhibiting the effects of sugar isogenesis (gluconeogenesis)   imeglimin also has potential protective effects on the survival and function of beta cells
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.